Form 4: Ionis Pharmaceuticals Director Michael R. Hayden Acquires Stock Options and Restricted Stock Units

Director Michael R. Hayden received stock options and restricted stock units from Ionis Pharmaceuticals as part of the company's Non-Employee Director Compensation Policy.

Summary

• On July 1, 2024, Michael R. Hayden, a director of Ionis Pharmaceuticals, acquired 10,111 non-qualified stock options with an exercise price of $47.11 and 4,079 restricted stock units (RSUs).
• These grants were adjusted to ensure that the director's annual equity compensation in 2024 does not exceed $450,000, based on the aggregate grant date fair value.
• The stock options vest 100% on either the first anniversary of the grant date (July 1, 2025) or the next regularly scheduled annual meeting of stockholders, whichever occurs earlier, and expire on June 30, 2034.
• The RSUs also vest 100% on either the first anniversary of the grant date or the next regularly scheduled annual meeting of stockholders, whichever occurs earlier, and will be delivered on the July 15th following the vesting date.
• Following these transactions, Hayden directly owns 10,111 derivative securities and 8,756 shares of common stock.

Sentiment

Score: 7

Explanation: The document reflects a routine equity grant to a director, which is generally viewed as a neutral to slightly positive event as it aligns interests. There are no indications of financial distress or unusual activity.

Positives

• The equity grants align the director's interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the director.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting and expiration dates of the granted securities.

Industry Context

Granting stock options and restricted stock units to directors is a common practice in the pharmaceutical industry to align their interests with those of the shareholders and incentivize long-term value creation.

Comparison to Industry Standards

• Director compensation packages vary widely across the pharmaceutical industry depending on company size, performance, and board structure.
• Companies like Amgen, Gilead Sciences, and Biogen also utilize a mix of cash and equity-based compensation for their directors.
• The $450,000 equity compensation limit appears to be within a reasonable range for a director at a company of Ionis Pharmaceuticals' size and market capitalization.

Stakeholder Impact

• The equity grants align the director's interests with those of the shareholders, potentially leading to better decision-making.
• The grants have a minor dilutive effect on existing shareholders.

Key Dates